Q3 2025 Dyadic International Inc Earnings Call Transcript

Nov 12, 2025 / 10:00 PM GMT

Release Date Price: $0.9414 (-3.69%)

Transcript 8-K10-Q

Key Points

Positve

Dyadic International Inc (DYAI) has successfully transitioned from a platform-centric R&D organization to a commercially focused biotechnology company.
The company achieved its first commercial bulk sale of a Dyadic-produced protein, marking a significant milestone in its commercial evolution.
Dyadic has rebranded as Dyadic Applied Biosolutions and enhanced its technology foundation with CRISPR Cas 9 gene editing capabilities.
The partnership with Proliant Health and Biologics is advancing towards a commercial launch of recombinant Human Albumin in early 2026, with Dyadic receiving milestone payments.
Dyadic's collaboration with Interlink aims to expand its market reach in Asia, particularly in Japan and South Korea, without significant internal infrastructure investment.

Negative

Total revenues for the quarter decreased to $1,165,000 from $1,958,000 in the same period a year ago, indicating a decline in financial performance.
The company reported a net loss of $1,976,000 for the third quarter of 2025, compared to a net loss of $203,000 in the same period a year ago.
Research and development expenses increased to $572,000, reflecting higher costs associated with active internal research initiatives.
General and administrative expenses rose to $1,481,000, driven by rebranding and business development expenses.
The company faces challenges in scaling its product offerings and securing OEM agreements for bulk sales, which may impact revenue growth.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

DYAI.OQ - Dyadic International Inc
Q3 2025 Dyadic International Inc Earnings Call
Nov 12, 2025 / 10:00PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Good evening and welcome to Dyadic International Q3 2025 conference call. Currently, all participants are in a listen-only mode. Following management's prepared remarks, there will be a brief question-and-answer session. As a reminder, this conference call is being recorded today, November 12, 2025.

I would now like to turn the call over to Ms. Pen Rawson, Dyadic's Chief Financial Officer. Please go ahead.

--------------------------------------------------------------------------------
Unidentified_2 [2]
--------------------------------------------------------------------------------
Thank you. Good evening and welcome everyone to Dyadic Q3 2025 conference call. I hope you have had the

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

7-Day Free Trial · Cancel Anytime

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.